Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant ZIKV E anticorps

ZIKV E Reactivité: Zika Virus (ZIKV) Func Hôte: Human Monoclonal ZKA64 unconjugated Recombinant Antibody
N° du produit ABIN6253501
  • Antigène Tous les produits ZIKV E
    ZIKV E (Zika Virus Envelope (ZIKV E))
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    • 6
    • 1
    Zika Virus (ZIKV)
    Hôte
    • 4
    • 3
    Human
    Clonalité
    • 6
    • 1
    Monoclonal
    Conjugué
    • 7
    Cet anticorp ZIKV E est non-conjugé
    Application
    • 6
    • 2
    • 1
    Functional Studies (Func)
    Fonction
    anti-Zika Virus Envelope Protein (EIII domain), mAb (rec.) (neutralizing) (ZKA64) (preservative free)
    Attributs du produit
    Recombinant Antibody. Recognizes and binds specifically to the EDIII domain of the Zika Virus envelope protein (ZIKV E). It does not cross-react with Dengue virus envelope protein (DENV E). Species cross-reactivity: Virus. Clone: ZKA64. Isotype: Human IgG1kappa. Applications: FUNC, FUNC (Blocking). Host: . Liquid. In PBS. The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.
    Pureté
    >95 % (SDS-PAGE)
    niveau d'endotoxine
    <0.001EU/μg
    Immunogène
    Zika Virus
    Clone
    ZKA64
    Isotype
    IgG1 kappa
  • Indications d'application
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    Lot specific
    Buffer
    Liquid. In PBS.
    Agent conservateur
    Without preservative
    Conseil sur la manipulation
    Avoid freeze/thaw cycles.
    Stock
    4 °C,-20 °C
    Stockage commentaire

    Short Term Storage: +4°C

    Long Term Storage: -20°C

    Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Stable for at least 3 months after receipt when stored at +4°C.

  • Antigène
    ZIKV E (Zika Virus Envelope (ZIKV E))
    Autre désignation
    Zika Virus Envelope Protein (ZIKV E Produits)
    Classe de substances
    Viral Protein
    Sujet

    Alternate Names/Synonyms: ZIKV E Protein

    Product Description: The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barré syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV.

Vous êtes ici:
Support technique